Stoke Therapeutics Inc (STOK) announced Loss for its first quarter that increased from the same period last year but beat the Street estimates.
The company's bottom line totaled -$26.37 million, or -$0.57 per share. This compares with -$22.55 million, or -$0.53 per share, in last year's first quarter.
Analysts on average had expected the company to earn -$0.61 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 18.1% to $4.22 million from $5.15 million last year.
Stoke Therapeutics Inc earnings at a glance (GAAP) :
-Earnings (Q1): -$26.37 Mln. vs. -$22.55 Mln. last year.
-EPS (Q1): -$0.57 vs. -$0.53 last year.
-Revenue (Q1): $4.22 Mln vs. $5.15 Mln last year.
For comments and feedback contact: editorial@rttnews.com